retatrutide 3 months A summary slide of the TRIUMPH-1 data presented today by Dr. Ania Jastreboff at #ADA2026 🚨 TRIUMPH-1: Phase Obesity Trial with Retatrutide 🚨 Retatrutide 💉, a once-weekly triple hormone receptor Reta – 3 Month Update

Important safety information includes a boxed warning for risk of thyroid C-cell tumors and contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

doi: 10.1007/s40263-014-0178-y

GLP-1RAs is currently widely used in clinical practice due to its significant benefits

Each receptor pathway has its own downstream signaling duration

In conclusion, GLP-1 receptor agonists represent a major advance in metabolic medicine and, based on current evidence, offer collateral benefits for male reproductive and sexual health rather than harm

The ~60% reduction in oral contraceptive absorption was specifically documented with tirzepatide